Nitrovin (difurazone), an antibacterial growth promoter, induces ROS-mediated paraptosis-like cell death by targeting thioredoxin reductase 1 (TrxR1)-Reference-Cited by-同舟云学术

Nitrovin (difurazone), an antibacterial growth promoter, induces ROS-mediated paraptosis-like cell death by targeting thioredoxin reductase 1 (TrxR1)

Published:2023-04 Issue: Volume:210 Page:115487
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Zhao Lin,Zhong Bingling,Zhu Yanyan,Zheng Haoyi,Wang Xumei,Hou Ying,Lu Jin-Jian,Ai Nana,Guo Xiuli,Ge Wei,Ma Yan-Yan,Chen Xiuping

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference52 articles.

1. Central nervous system gliomas;Reni;Crit. Rev. Oncol. Hematol.,2017

2. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment;Hanif;Asian Pac. J. Cancer Prev.,2017

3. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;Stupp;Lancet Oncol.,2009

4. H. Strobel et al., Temozolomide and other alkylating agents in glioblastoma therapy, Biomedicines 7(3) (2019).

5. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N. Engl. J. Med.,2005

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oxidative cell death in cancer: mechanisms and therapeutic opportunities;Cell Death & Disease;2024-08-01

2. Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review;Journal of Cancer Research and Clinical Oncology;2024-04-25

3. Targeting paraptosis in cancer: opportunities and challenges;Cancer Gene Therapy;2024-01-04

4. Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells;International Journal of Biological Sciences;2024

5. Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer;Acta Materia Medica;2024